Clinical Trial Update: R115777 in Treating Patients With Relapsed Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial results update for tipifarnib (R115777) in relapsed small cell lung cancer. The study has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Zarnestra (tipifarnib) (tipifarnib)

Snippet

Sponsor: NYU Langone Health | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED